Pubblicazioni

Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7)

2021 - AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS

Santini, D; Stellato, M; De Giorgi, U; Pantano, F; De Lisi, D; Casadei, C; Maruzzo, M; Bimbatti, D; Naglieri, E; Buti, S; Bersanelli, M; De Vivo, R; Di Lorenzo, G; Sbrana, A; Verzoni, E; Soraru', M; Fornarini, G; Mucciarini, C; Grillone, F; Mini, E; Vignani, F; Attademo, L; Pignata, S; Procopio, G

Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: An expert panel consensus

2015 - FUTURE ONCOLOGY

Peris, K.; Licitra, L.; Ascierto, P. A.; Corvo, R.; Simonacci, M.; Picciotto, F.; Gualdi, G.; Pellacani, G.; Santoro, A.